Reported Earnings • Jul 15
Second quarter 2026 earnings released: EPS: CN¥0.35 (vs CN¥0.31 in 2Q 2025) Second quarter 2026 results: EPS: CN¥0.35 (up from CN¥0.31 in 2Q 2025). Revenue: CN¥2.04b (down 8.8% from 2Q 2025). Net income: CN¥522.4m (up 14% from 2Q 2025). Profit margin: 26% (up from 21% in 2Q 2025). The increase in margin was driven by lower expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 2% per year. Announcement • Jun 30
Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2026 Results on Aug 22, 2026 Tasly Pharmaceutical Group Co., Ltd announced that they will report first half, 2026 results on Aug 22, 2026 Reported Earnings • Apr 25
First quarter 2026 earnings released: EPS: CN¥0.25 (vs CN¥0.21 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.25 (up from CN¥0.21 in 1Q 2025). Revenue: CN¥2.16b (up 5.3% from 1Q 2025). Net income: CN¥370.2m (up 18% from 1Q 2025). Profit margin: 17% (up from 15% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Mar 30
Tasly Pharmaceutical Group Co., Ltd to Report Q1, 2026 Results on Apr 25, 2026 Tasly Pharmaceutical Group Co., Ltd announced that they will report Q1, 2026 results on Apr 25, 2026 Major Estimate Revision • Mar 26
Consensus EPS estimates fall by 23%, revenue upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from CN¥8.45b to CN¥8.99b. EPS estimate fell from CN¥1.17 to CN¥0.896 per share. Net income forecast to grow 21% next year vs 23% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥17.24 to CN¥16.88. Share price fell 2.3% to CN¥13.78 over the past week. Announcement • Mar 23
Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, Apr 17, 2026 Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, Apr 17, 2026, at 15:30 China Standard Time. Location: The Company's Meeting Room, Tianjin China Reported Earnings • Mar 20
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.74 (up from CN¥0.64 in FY 2024). Revenue: CN¥8.24b (down 3.1% from FY 2024). Net income: CN¥1.10b (up 16% from FY 2024). Profit margin: 13% (up from 11% in FY 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 6.1%. Earnings per share (EPS) also missed analyst estimates by 7.3%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Feb 24
Consensus EPS estimates increase by 23%, revenue downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from CN¥9.37b to CN¥8.45b. EPS estimate rose from CN¥0.951 to CN¥1.17. Net income forecast to grow 58% next year vs 25% growth forecast for Pharmaceuticals industry in China. Consensus price target broadly unchanged at CN¥17.24. Share price was steady at CN¥14.68 over the past week. Reported Earnings • Feb 10
Full year 2025 earnings released: EPS: CN¥0.74 (vs CN¥0.64 in FY 2024) Full year 2025 results: EPS: CN¥0.74 (up from CN¥0.64 in FY 2024). Revenue: CN¥8.24b (down 3.1% from FY 2024). Net income: CN¥1.11b (up 16% from FY 2024). Profit margin: 13% (up from 11% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Announcement • Jan 26
U.S. Food and Drug Administration Accepts Tasly 3P Characterization of Mscs Assay into Its Regulatory Framework In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal Stromal Cells (MSCs) was accepted by the U.S. Food and Drug Administration (FDA). The agency's Master File acknowledgement letter, issued on January 9, 2026, incorporates the "Tasly 3P Characterization of MSCs Assay" (MF 32345) into its regulatory framework. This step provides long-sought guidance to ensure the consistent, safe, and effective clinical use of MSCs. Historically misclassified as stem cells, MSCs have been associated with variable clinical outcomes due to a lack of specific quality benchmarks. The newly recognized " 3P " assay directly addresses this by evaluating three core attributes: Property (cell identity), Purity (freedom from contaminants), and Potency (functional activity). This focus ensures that therapeutic MSC products are accurately defined, devoid of heterogeneous cell populations, and biologically potent. The introduction of the Tasly 3P assay marks a pivotal shift toward normalized characterization of MSCs. It mitigates historical risks such as tumor formation and therapeutic inconsistency while empowering clinicians and patients to verify cell quality before treatment. As the first FDA-recognized protocol of its kind, it establishes a new benchmark for the field and accelerates the transition in regenerative medicine from a stem-cell-centric model to a stromal cell-focused paradigm. By endorsing a standard that aligns with the modern scientific understanding-- that MSCs primarily function via paracrine signaling, not differentiation--the FDA is closing a critical regulatory gap. This alignment with updated International Society for Cell & Gene Therapy guidelines is poised to streamline Investigational New Drug applications, enhance clinical trial reliability, and foster global harmonization in MSC product evaluation. Announcement • Dec 26
Tasly Pharmaceutical Group Co., Ltd to Report Fiscal Year 2025 Results on Mar 20, 2026 Tasly Pharmaceutical Group Co., Ltd announced that they will report fiscal year 2025 results on Mar 20, 2026 Buy Or Sell Opportunity • Dec 01
Now 21% overvalued Over the last 90 days, the stock has fallen 4.8% to CN¥15.59. The fair value is estimated to be CN¥12.92, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 40% in the next 2 years. Buy Or Sell Opportunity • Nov 11
Now 20% overvalued Over the last 90 days, the stock has fallen 4.6% to CN¥15.55. The fair value is estimated to be CN¥12.92, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 40% in the next 2 years. Reported Earnings • Oct 28
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: CN¥0.14 (up from CN¥0.12 in 3Q 2024). Revenue: CN¥2.02b (down 3.3% from 3Q 2024). Net income: CN¥209.7m (up 17% from 3Q 2024). Profit margin: 10% (up from 8.6% in 3Q 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 7.9%. Earnings per share (EPS) also missed analyst estimates by 18%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Declared Dividend • Oct 12
Dividend reduced to CN¥0.21 Dividend of CN¥0.21 is 19% lower than last year. Ex-date: 17th October 2025 Payment date: 17th October 2025 Dividend yield will be 3.0%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (67% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 6.6% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 56% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Sep 30
Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2025 Results on Oct 25, 2025 Tasly Pharmaceutical Group Co., Ltd announced that they will report Q3, 2025 results on Oct 25, 2025 Price Target Changed • Aug 20
Price target increased by 11% to CN¥18.09 Up from CN¥16.33, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of CN¥17.41. Stock is up 29% over the past year. The company is forecast to post earnings per share of CN¥0.81 for next year compared to CN¥0.64 last year. Reported Earnings • Aug 19
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: EPS: CN¥0.31 (up from CN¥0.25 in 2Q 2024). Revenue: CN¥2.23b (down 3.9% from 2Q 2024). Net income: CN¥460.4m (up 25% from 2Q 2024). Profit margin: 21% (up from 16% in 2Q 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 8.5%. Earnings per share (EPS) exceeded analyst estimates by 24%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 20% per year. Buy Or Sell Opportunity • Jul 15
Now 20% undervalued Over the last 90 days, the stock has risen 2.0% to CN¥15.57. The fair value is estimated to be CN¥19.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 8.9%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 48% in the next 2 years. Announcement • Jun 30
Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2025 Results on Aug 23, 2025 Tasly Pharmaceutical Group Co., Ltd announced that they will report first half, 2025 results on Aug 23, 2025 Buy Or Sell Opportunity • Jun 18
Now 20% undervalued Over the last 90 days, the stock has risen 2.8% to CN¥15.55. The fair value is estimated to be CN¥19.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 8.9%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 44% in the next 2 years. Major Estimate Revision • Mar 03
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥9.30b to CN¥8.95b. EPS estimate also fell from CN¥0.85 per share to CN¥0.759 per share. Net income forecast to grow 19% next year vs 32% growth forecast for Pharmaceuticals industry in China. Consensus price target of CN¥16.61 unchanged from last update. Share price was steady at CN¥14.99 over the past week. Reported Earnings • Feb 25
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.64 (down from CN¥0.72 in FY 2023). Revenue: CN¥8.50b (down 2.0% from FY 2023). Net income: CN¥955.6m (down 11% from FY 2023). Profit margin: 11% (down from 12% in FY 2023). Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 7.6%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • Feb 25
Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, Mar 17, 2025 Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, Mar 17, 2025, at 15:00 China Standard Time. Location: The Company's Meeting Room, Tianjin China Announcement • Dec 27
Tasly Pharmaceutical Group Co., Ltd to Report Fiscal Year 2024 Results on Mar 04, 2025 Tasly Pharmaceutical Group Co., Ltd announced that they will report fiscal year 2024 results on Mar 04, 2025 Major Estimate Revision • Nov 01
Consensus EPS estimates fall by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥9.10b to CN¥8.96b. EPS estimate also fell from CN¥0.802 per share to CN¥0.693 per share. Net income forecast to grow 42% next year vs 35% growth forecast for Pharmaceuticals industry in China. Consensus price target of CN¥17.36 unchanged from last update. Share price fell 2.2% to CN¥14.90 over the past week. Reported Earnings • Oct 26
Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.22 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.22 in 3Q 2023). Revenue: CN¥2.09b (down 4.1% from 3Q 2023). Net income: CN¥179.9m (down 45% from 3Q 2023). Profit margin: 8.6% (down from 15% in 3Q 2023). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Upcoming Dividend • Oct 03
Upcoming dividend of CN¥0.26 per share Eligible shareholders must have bought the stock before 10 October 2024. Payment date: 10 October 2024. Payout ratio is on the higher end at 86%, however this is supported by cash flows. Trailing yield: 3.2%. Within top quartile of Chinese dividend payers (2.2%). Higher than average of industry peers (1.7%). Announcement • Sep 30
Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024 Tasly Pharmaceutical Group Co., Ltd announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥16.15, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 31% over the past three years. Reported Earnings • Aug 24
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2024 results: EPS: CN¥0.25 (down from CN¥0.29 in 2Q 2023). Revenue: CN¥2.32b (flat on 2Q 2023). Net income: CN¥367.1m (down 17% from 2Q 2023). Profit margin: 16% (down from 19% in 2Q 2023). Revenue missed analyst estimates by 8.6%. Earnings per share (EPS) exceeded analyst estimates by 14%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Buy Or Sell Opportunity • Jul 31
Now 23% overvalued Over the last 90 days, the stock has fallen 8.9% to CN¥14.08. The fair value is estimated to be CN¥11.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 22%. Revenue is forecast to grow by 16% in 2 years. Earnings are forecast to grow by 31% in the next 2 years. Announcement • Jun 28
Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 24, 2024 Tasly Pharmaceutical Group Co., Ltd announced that they will report first half, 2024 results on Aug 24, 2024 Price Target Changed • Jun 15
Price target increased by 8.7% to CN¥16.17 Up from CN¥14.87, the current price target is an average from 5 analysts. New target price is 20% above last closing price of CN¥13.47. Stock is down 7.7% over the past year. The company is forecast to post earnings per share of CN¥0.82 for next year compared to CN¥0.72 last year. Buy Or Sell Opportunity • Jun 07
Now 20% overvalued Over the last 90 days, the stock has fallen 18% to CN¥13.72. The fair value is estimated to be CN¥11.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 22%. Revenue is forecast to grow by 16% in 2 years. Earnings are forecast to grow by 31% in the next 2 years. Declared Dividend • May 25
Dividend of CN¥0.33 announced Shareholders will receive a dividend of CN¥0.33. Ex-date: 29th May 2024 Payment date: 29th May 2024 Dividend yield will be 2.3%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (45% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has increased by an average of 2.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 38% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.18 in 1Q 2023). Revenue: CN¥2.05b (down 1.5% from 1Q 2023). Net income: CN¥295.2m (up 11% from 1Q 2023). Profit margin: 14% (up from 13% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Price Target Changed • Apr 18
Price target decreased by 7.0% to CN¥13.88 Down from CN¥14.92, the current price target is an average from 4 analysts. New target price is 10% below last closing price of CN¥15.42. Stock is down 0.4% over the past year. The company is forecast to post earnings per share of CN¥0.89 for next year compared to CN¥0.72 last year. Announcement • Apr 16
Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024 Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Tianjin China Buy Or Sell Opportunity • Apr 16
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.5% to CN¥14.90. The fair value is estimated to be CN¥18.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 17% over the last 3 years. Earnings per share has declined by 22%. Revenue is forecast to grow by 16% in 2 years. Earnings are forecast to grow by 30% in the next 2 years. Announcement • Mar 29
Tasly Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024 Tasly Pharmaceutical Group Co., Ltd announced that they will report Q1, 2024 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥15.89, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total returns to shareholders of 23% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥18.73 per share. Buy Or Sell Opportunity • Feb 05
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 8.0% to CN¥13.64. The fair value is estimated to be CN¥17.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 17% over the last 3 years. Earnings per share has declined by 22%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 25% in the next 2 years. Reported Earnings • Oct 31
Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.047 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.22 (up from CN¥0.047 in 3Q 2022). Revenue: CN¥2.18b (up 4.3% from 3Q 2022). Net income: CN¥325.3m (up 344% from 3Q 2022). Profit margin: 15% (up from 3.5% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023 Tasly Pharmaceutical Group Co., Ltd announced that they will report Q3, 2023 results on Oct 28, 2023 Price Target Changed • Sep 22
Price target increased by 10% to CN¥12.76 Up from CN¥11.58, the current price target is an average from 4 analysts. New target price is 6.0% below last closing price of CN¥13.57. Stock is up 44% over the past year. The company is forecast to post earnings per share of CN¥0.73 next year compared to a net loss per share of CN¥0.17 last year. Price Target Changed • Sep 19
Price target decreased by 13% to CN¥10.64 Down from CN¥12.28, the current price target is an average from 3 analysts. New target price is 24% below last closing price of CN¥14.06. Stock is up 43% over the past year. The company is forecast to post earnings per share of CN¥0.64 next year compared to a net loss per share of CN¥0.17 last year. Major Estimate Revision • Sep 01
Consensus EPS estimates fall by 19% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥9.35b to CN¥9.25b. EPS estimate also fell from CN¥0.784 per share to CN¥0.639 per share. Net income forecast to grow 31% next year vs 28% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥12.28 to CN¥11.58. Share price rose 6.1% to CN¥13.99 over the past week. Reported Earnings • Aug 26
Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.10 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.29 (up from CN¥0.10 in 2Q 2022). Revenue: CN¥2.31b (up 7.9% from 2Q 2022). Net income: CN¥441.0m (up 195% from 2Q 2022). Profit margin: 19% (up from 7.0% in 2Q 2022). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Buying Opportunity • Jul 18
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 6.6%. The fair value is estimated to be CN¥18.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 32% over the last 3 years. Earnings per share has declined by 15%. Revenue is forecast to grow by 16% in 2 years. Earnings is forecast to grow by 135% in the next 2 years. Major Estimate Revision • Jun 30
Consensus EPS estimates increase by 12% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from CN¥0.735 to CN¥0.82. Revenue forecast steady at CN¥9.44b. Net income forecast to grow 110% next year vs 31% growth forecast for Pharmaceuticals industry in China. Consensus price target broadly unchanged at CN¥12.20. Share price rose 2.8% to CN¥14.51 over the past week. Announcement • Jun 28
Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 26, 2023 Tasly Pharmaceutical Group Co., Ltd announced that they will report first half, 2023 results on Aug 26, 2023 Buying Opportunity • Jun 19
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 1.5%. The fair value is estimated to be CN¥18.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 32% over the last 3 years. Earnings per share has declined by 15%. Revenue is forecast to grow by 17% in 2 years. Earnings is forecast to grow by 127% in the next 2 years. Buying Opportunity • May 11
Now 21% undervalued Over the last 90 days, the stock is up 24%. The fair value is estimated to be CN¥18.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 32% over the last 3 years. Earnings per share has declined by 15%. Revenue is forecast to grow by 17% in 2 years. Earnings is forecast to grow by 127% in the next 2 years. Price Target Changed • May 03
Price target increased by 9.3% to CN¥12.10 Up from CN¥11.07, the current price target is an average from 4 analysts. New target price is 20% below last closing price of CN¥15.14. Stock is up 44% over the past year. The company is forecast to post earnings per share of CN¥0.73 next year compared to a net loss per share of CN¥0.17 last year. Price Target Changed • Apr 25
Price target increased by 7.3% to CN¥11.79 Up from CN¥10.99, the current price target is an average from 4 analysts. New target price is 22% below last closing price of CN¥15.05. Stock is up 37% over the past year. The company is forecast to post earnings per share of CN¥0.73 next year compared to a net loss per share of CN¥0.17 last year. Reported Earnings • Mar 29
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: CN¥0.17 loss per share (down from CN¥1.57 profit in FY 2021). Revenue: CN¥8.59b (up 8.1% from FY 2021). Net loss: CN¥256.5m (down 111% from profit in FY 2021). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 42%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Price Target Changed • Mar 07
Price target increased by 8.0% to CN¥10.99 Up from CN¥10.18, the current price target is an average from 4 analysts. New target price is 19% below last closing price of CN¥13.62. Stock is down 3.7% over the past year. The company is forecast to post a net loss per share of CN¥0.056 compared to earnings per share of CN¥1.57 last year. Major Estimate Revision • Feb 23
Consensus EPS estimates fall by 35% The consensus outlook for fiscal year 2022 has been updated. 2022 EPS estimate fell from CN¥0.34 to CN¥0.22 per share. Revenue forecast steady at CN¥8.44b. Net income forecast to grow 81% next year vs 35% growth forecast for Pharmaceuticals industry in China. Consensus price target of CN¥10.13 unchanged from last update. Share price rose 13% to CN¥13.95 over the past week. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥14.02, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total loss to shareholders of 7.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥6.56 per share. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. 3 independent directors (6 non-independent directors). Vice Chairman Xiaomeng Jiang was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 26
Third quarter 2022 earnings released: EPS: CN¥0.047 (vs CN¥0.32 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.047 (down from CN¥0.32 in 3Q 2021). Revenue: CN¥2.09b (up 7.5% from 3Q 2021). Net income: CN¥73.3m (down 85% from 3Q 2021). Profit margin: 3.5% (down from 25% in 3Q 2021). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Price Target Changed • Oct 22
Price target decreased to CN¥10.19 Down from CN¥11.31, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of CN¥10.56. Stock is down 24% over the past year. The company is forecast to post earnings per share of CN¥0.34 for next year compared to CN¥1.57 last year. Major Estimate Revision • Aug 26
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from CN¥8.13b to CN¥8.32b. EPS estimate fell from CN¥0.56 to CN¥0.34 per share. Net income forecast to shrink 7.4% next year vs 30% growth forecast for Pharmaceuticals industry in China . Consensus price target down from CN¥11.31 to CN¥10.96. Share price was steady at CN¥10.12 over the past week. Reported Earnings • Aug 20
Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.10 (down from CN¥0.45 in 2Q 2021). Revenue: CN¥2.14b (up 3.8% from 2Q 2021). Net income: CN¥149.4m (down 78% from 2Q 2021). Profit margin: 7.0% (down from 33% in 2Q 2021). Over the next year, revenue is forecast to grow 3.1%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Major Estimate Revision • Jun 01
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from CN¥0.59 to CN¥0.66. Revenue forecast steady at CN¥8.15b. Net income forecast to shrink 28% next year vs 25% growth forecast for Healthcare industry in China . Consensus price target down from CN¥13.06 to CN¥11.44. Share price was steady at CN¥10.34 over the past week. Major Estimate Revision • May 17
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from CN¥8.51b to CN¥8.18b. EPS estimate rose from CN¥0.46 to CN¥0.59. Net income forecast to shrink 5.4% next year vs 25% growth forecast for Healthcare industry in China . Consensus price target down from CN¥14.34 to CN¥13.06. Share price fell 2.7% to CN¥10.46 over the past week. Major Estimate Revision • May 02
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from CN¥8.28b to CN¥8.51b. EPS estimate fell from CN¥0.82 to CN¥0.46 per share. Net income forecast to shrink 42% next year vs 22% growth forecast for Healthcare industry in China . Consensus price target down from CN¥16.70 to CN¥14.34. Share price fell 13% to CN¥10.54 over the past week. Price Target Changed • Apr 28
Price target decreased to CN¥14.34 Down from CN¥16.90, the current price target is an average from 4 analysts. New target price is 44% above last closing price of CN¥9.94. Stock is down 28% over the past year. The company is forecast to post earnings per share of CN¥0.69 for next year compared to CN¥1.57 last year. Reported Earnings • Apr 27
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: CN¥0.37 loss per share (down from CN¥0.21 profit in 1Q 2021). Revenue: CN¥1.87b (up 6.0% from 1Q 2021). Net loss: CN¥557.2m (down 273% from profit in 1Q 2021). Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 4.9%, compared to a 23% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. 3 independent directors (6 non-independent directors). Vice Chairman Xiaomeng Jiang was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Major Estimate Revision • Apr 21
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from CN¥8.58b to CN¥8.28b. EPS estimate rose from CN¥0.73 to CN¥0.82. Net income forecast to shrink 47% next year vs 18% growth forecast for Healthcare industry in China . Consensus price target broadly unchanged at CN¥16.70. Share price fell 2.2% to CN¥13.45 over the past week. Major Estimate Revision • Apr 07
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from CN¥8.01b to CN¥8.58b. EPS estimate fell from CN¥0.95 to CN¥0.73 per share. Net income forecast to shrink 53% next year vs 16% growth forecast for Healthcare industry in China . Consensus price target up from CN¥15.95 to CN¥16.90. Share price fell 4.7% to CN¥14.59 over the past week. Price Target Changed • Apr 06
Price target increased to CN¥16.52 Up from CN¥15.42, the current price target is an average from 4 analysts. New target price is 10% above last closing price of CN¥14.98. Stock is up 13% over the past year. The company is forecast to post earnings per share of CN¥0.77 for next year compared to CN¥1.57 last year. Reported Earnings • Apr 01
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥1.57 (up from CN¥0.75 in FY 2020). Revenue: CN¥7.95b (down 41% from FY 2020). Net income: CN¥2.36b (up 110% from FY 2020). Profit margin: 30% (up from 8.3% in FY 2020). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) also surpassed analyst estimates by 62%. Over the next year, revenue is forecast to stay flat compared to a 19% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Major Estimate Revision • Dec 02
Consensus EPS estimates fall to CN¥1.03 The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from CN¥7.59b to CN¥7.47b. EPS estimate also fell from CN¥1.22 to CN¥1.03. Net income forecast to shrink 2.6% next year vs 13% growth forecast for Healthcare industry in China . Consensus price target broadly unchanged at CN¥15.52. Share price rose 2.7% to CN¥13.73 over the past week. Reported Earnings • Oct 27
Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.27 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: CN¥1.94b (down 30% from 3Q 2020). Net income: CN¥478.8m (up 16% from 3Q 2020). Profit margin: 25% (up from 15% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 12% per year. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.26 in 2Q 2020) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: CN¥2.06b (down 56% from 2Q 2020). Net income: CN¥679.2m (up 74% from 2Q 2020). Profit margin: 33% (up from 8.4% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 16% per year. Major Estimate Revision • Apr 30
Consensus revenue estimates fall to CN¥7.67b The consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from CN¥11.1b to CN¥7.67b. EPS estimate fell from CN¥0.80 to CN¥0.73 per share. Net income forecast to grow 1.0% next year vs 14% growth forecast for Healthcare industry in China. Consensus price target broadly unchanged at CN¥17.22. Share price was steady at CN¥13.82 over the past week. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.20 in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CN¥1.76b (down 55% from 1Q 2020). Net income: CN¥323.0m (up 9.5% from 1Q 2020). Profit margin: 18% (up from 7.5% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Announcement • Mar 05
Tasly Pharmaceutical Group Co., Ltd to Report Fiscal Year 2020 Results on Mar 30, 2021 Tasly Pharmaceutical Group Co., Ltd announced that they will report fiscal year 2020 results on Mar 30, 2021 Announcement • Jan 28
Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) dropped from S&P Global BMI Index Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) dropped from S&P Global BMI Index Is New 90 Day High Low • Jan 28
New 90-day low: CN¥13.57 The company is down 22% from its price of CN¥17.50 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥7.10 per share. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥14.49 The company is down 17% from its price of CN¥17.56 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥7.10 per share. Price Target Changed • Jan 01
Price target raised to CN¥19.43 Up from CN¥18.13, the current price target is an average from 6 analysts. The new target price is 31% above the current share price of CN¥14.79. As of last close, the stock is down 5.6% over the past year. 
